熱門資訊> 正文
Tiziana发布了阿尔茨海默氏症铅资产的有利PET扫描数据
2025-05-09 19:33
- Tiziana Life Sciences (NASDAQ:TLSA) announced Friday that PET scan data from a patient with moderate Alzheimer's disease who received its lead asset, intranasal foralumab, indicated a sharp decline in microglia activation, a pathological hallmark of neurodegenerative diseases.
- Shares of the U.K.-based biotech added ~5% in the premarket after the announcement.
- The patient received intranasal foralumab over three months under an expanded access program, an FDA-authorized pathway designed to allow patients with serious diseases to receive an investigational medical product outside of clinical studies.
- Microglial activation is widely thought to be a key component of Alzheimer’s and other neurodegenerative diseases, and in addition to beta-amyloid and tau protein, the process is believed to be a contributory factor for AD.
- “This PET scan result showing a dampening of microglial activation by nasal foralumab in a patient with moderate Alzheimer’s disease demonstrates the potential for foralumab to fight many neurologic diseases by treating neuroinflammation,” said TLSA’s founder, Gabriele Cerrone.
More on Tiziana Life Sciences
- Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
- Tiziana rises on positive results in multiple sclerosis treatment study
- Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment
- Financial information for Tiziana Life Sciences
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
